Patients in the experimental group of ND0612 demonstrated favourable efficacy over IR-LD/CD. Data showed a statistically significant increase (p<0.0001) of 1.72 hours in “ON” time without troublesome dyskinesia. The trial also demonstrated positive and clinically meaningful results for the first four secondary endpoints, including a reduction of “OFF” time (p<0.0001).
Mitsubishi Tanabe Pharma Corporation has ... - Cure Parkinson's
Mitsubishi Tanabe Pharma Corporation has announced that a Phase III trial of its Parkinson’s disease candidate has met its primary endpoint.
Written by
Farooqji
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
I know several posts have been made regarding the exanatide trials, but I just stumbled across this...
Isn't this the most dramatic trial so far?
I haven't seen a reference to it on this site. Does anyone know if this has been discussed?
When I...
Benfotiamine In The Mix For PD Again?
The following new animal study (December 2023) suggests that the fat soluble form of vitamin B1,...
How many know that H2, hydrogen water has positive effects for those with Parkinsons? I didn't know.
PMID: 23400965 DOI: 10.1002/mds.25375
Abstract
Background: Oxidative stress is involved in the...
Has anyone tried hydrogen water for PD?
Has anyone tried hydrogen water for PD?
This was a double-blind (placebo controlled) study which...
Related Posts
This is worth your time to look at ... Benedlife.com says it has clinical proof their supplement (take with your regular PD meds) WORKS!
Dr Matthew Best Prebiotics and Probiotics for Women
Thumbs up for Nilotinib - Phase II Trials
Is There A Natural And Available Alternative To Fecal Microbiome Transplantation (FMT) ?- Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease
